Safety, Tolerability and Pharmacokinetics of Orally Administered BC‑3781, a Novel Antimicrobial

Trial Profile

Safety, Tolerability and Pharmacokinetics of Orally Administered BC‑3781, a Novel Antimicrobial

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2013

At a glance

  • Drugs Lefamulin (Primary)
  • Indications Community-acquired pneumonia; Respiratory tract infections; Sexually transmitted infections; Skin and soft tissue infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Nabriva Therapeutics
  • Most Recent Events

    • 24 Oct 2013 New trial record
    • 10 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top